These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30131091)

  • 21. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
    Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
    Tan AC; Seet AOL; Lai GGY; Lim TH; Lim AST; Tan GS; Takano A; Tai DWM; Tan TJY; Lam JYC; Ng MCH; Tan WL; Ang MK; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim WT; Tan EH; Lim TKH; Tan DSW
    J Thorac Oncol; 2020 Dec; 15(12):1928-1934. PubMed ID: 32866654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralsetinib treatment for multiple
    Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
    J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
    Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
    Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
    Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
    Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation.
    Tian P; Wang Y; Wang W; Li Y; Wang K; Cheng X; Tang Y; Han-Zhang H; Ye J; Chuai S; Li W
    Lung Cancer; 2018 Oct; 124():205-210. PubMed ID: 30268462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
    Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
    Ferrara R; Auger N; Auclin E; Besse B
    J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.